A Phase I, Open-label Study to Assess the Safety and Tolerability of AZD0530 in Combination With Carboplatin and/or Paclitaxel Chemotherapy in Patients With Solid Tumours
Interventional
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the safety and tolerability of AZD0530 in combination with carboplatin and/or paclitaxel regimens with solid tumours by assessment of AEs, physical examination, BP, pulse, ECG, laboratory findings, PFTs and thoracic CT scans.
Assessed at each visit
No
Steinar Aamdal, MD
Principal Investigator
Radium Hospital, Norway
United Kingdom: Medicines and Healthcare Products Regulatory Agency
D8180C00023
NCT00496028
March 2007
March 2010
Name | Location |
---|